The Hypoglycemic Action of Ketones. II. Evidence for a Stimulatory Feedback of Ketones on the Pancreatic Beta Cells

^{Department of Internal Medicine, the University of Texas Southwestern Medical School, Dallas, Texas}

During tenure of U. S. Public Health Service post-doctoral fellowship (APD-17,224) of the National Institute for Arthritis and Metabolic Diseases.

During tenure of a predoctoral fellowship.

Submitted for publication August 5, 1963; accepted November 7, 1963.

This work has been supported in large part by U. S. Public Health Service grant A-4236 from the National Institute for Arthritis and Metabolic Diseases and also by grants from the Upjohn and Pfizer Companies.

Presented before the Fifty-Fifth Annual Meeting of the American Society for Clinical Investigation, April 29, 1963.

Find articles by Madison, L. in: JCI | PubMed | Google Scholar

^{Department of Internal Medicine, the University of Texas Southwestern Medical School, Dallas, Texas}

During tenure of U. S. Public Health Service post-doctoral fellowship (APD-17,224) of the National Institute for Arthritis and Metabolic Diseases.

During tenure of a predoctoral fellowship.

Submitted for publication August 5, 1963; accepted November 7, 1963.

This work has been supported in large part by U. S. Public Health Service grant A-4236 from the National Institute for Arthritis and Metabolic Diseases and also by grants from the Upjohn and Pfizer Companies.

Presented before the Fifty-Fifth Annual Meeting of the American Society for Clinical Investigation, April 29, 1963.

Find articles by Mebane, D. in: JCI | PubMed | Google Scholar

^{Department of Internal Medicine, the University of Texas Southwestern Medical School, Dallas, Texas}

During tenure of U. S. Public Health Service post-doctoral fellowship (APD-17,224) of the National Institute for Arthritis and Metabolic Diseases.

During tenure of a predoctoral fellowship.

Submitted for publication August 5, 1963; accepted November 7, 1963.

This work has been supported in large part by U. S. Public Health Service grant A-4236 from the National Institute for Arthritis and Metabolic Diseases and also by grants from the Upjohn and Pfizer Companies.

Presented before the Fifty-Fifth Annual Meeting of the American Society for Clinical Investigation, April 29, 1963.

Find articles by Unger, R. in: JCI | PubMed | Google Scholar

^{Department of Internal Medicine, the University of Texas Southwestern Medical School, Dallas, Texas}

During tenure of U. S. Public Health Service post-doctoral fellowship (APD-17,224) of the National Institute for Arthritis and Metabolic Diseases.

During tenure of a predoctoral fellowship.

Submitted for publication August 5, 1963; accepted November 7, 1963.

This work has been supported in large part by U. S. Public Health Service grant A-4236 from the National Institute for Arthritis and Metabolic Diseases and also by grants from the Upjohn and Pfizer Companies.

Presented before the Fifty-Fifth Annual Meeting of the American Society for Clinical Investigation, April 29, 1963.

Find articles by Lochner, A. in: JCI | PubMed | Google Scholar